Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice.
Chemotherapy
Comorbidities
Concurrent treatment
Elderly
Immunotherapy
Radiotherapy
Sequential treatment
Stage III lung cancer
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
31
05
2020
revised:
19
02
2021
accepted:
29
05
2021
pubmed:
5
6
2021
medline:
14
7
2021
entrez:
4
6
2021
Statut:
ppublish
Résumé
Treatment of locally advanced NSCLC (LA-NSCLC) is focused on multimodal strategy, including chemotherapy and radiotherapy (in combination or as alternative treatments), followed by surgery in selected cases. Recently, durvalumab consolidation after definitive chemo-radiation has shown a meaningful overall survival benefit. However, it is important to note that elderly patients represent a high proportion of NSCLC population and frailty and comorbidities can significantly limit treatment options. Indeed, elderly patients are under-represented in clinical trials and data to drive treatment selection in this category of patients are scanty. Available data, main issues and controversies on multimodal treatment in elderly LA-NSCLC patients will be reviewed in this paper.
Identifiants
pubmed: 34087343
pii: S1040-8428(21)00166-9
doi: 10.1016/j.critrevonc.2021.103378
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103378Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.